Corporate ProfileOncobiologics is a clinical stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex biosimilar therapeutics. Our current focus is on technically challenging and commercially attractive monoclonal antibodies (mAbs), in the disease areas of immunology and oncology. Our strategy is to leverage our BioSymphony™ Platform to cost-effectively develop these biosimilars on an accelerated timeline, which is fundamental to our success and we believe positions us to be a leading biosimilar company.
November 14, 2016
Oncobiologics Announces Presentation of Final Data from Phase 1 Clinical Study of ONS-3010 (HUMIRA® Biosimilar)more >
August 31, 2016
Oncobiologics to Present at BioCentury’s NewsMakers in the Biotech Industry Conferencemore >
July 06, 2016